Asensus Surgical, Inc. (ASXC)
Pre-market:
| Previous close | 0.2500 |
| Open | 0.2560 |
| Bid | 0.2200 x 900 |
| Ask | 0.0000 x 2900 |
| Day's range | 0.2499 - 0.2574 |
| 52-week range | 0.2000 - 0.7000 |
| Volume | |
| Avg. volume | 1,607,241 |
| Market cap | 67.996M |
| Beta (5Y monthly) | 1.48 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.3100 |
| Earnings date | 09 May 2024 - 13 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 0.35 |
GlobeNewswireAsensus Surgical, Inc. Announces Non-Binding Acquisition Proposal and Exclusivity Arrangement with KARL STORZ SE & Co. KG
KARL STORZ to provide up to $20 million in bridge financingRESEARCH TRIANGLE PARK, N.C., April 03, 2024 (GLOBE NEWSWIRE) -- Asensus Surgical, Inc. (NYSE American: ASXC) (“Asensus” or the “Company”), a medical device company that is digitizing the interface between the surgeon and the patient, today announced that it has entered into a non-binding letter of intent (the “letter of intent”) with KARL STORZ SE & Co. KG, an independent, family-owned global medical technology company (“KARL STORZ”) to
- GlobeNewswire
Asensus Surgical, Inc. Reports Operating and Financial Results for the Fourth Quarter 2023 and Full Year 2023
RESEARCH TRIANGLE PARK, N.C., March 21, 2024 (GLOBE NEWSWIRE) -- Asensus Surgical, Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and the patient, announced its operating and financial results for the fourth quarter and full year 2023. Full Year Highlights Completed in vivo evaluation of the LUNA™ Surgical System by nine independent surgeons through thirteen procedures across gynecology, urology, and general surgeryOver 3,550 surgical pr
- GlobeNewswire
Asensus Surgical, Inc. Schedules Fourth Quarter and Full Year 2023 Financial and Operating Results Conference Call for March 21, 2024
RESEARCH TRIANGLE PARK, N.C., March 15, 2024 (GLOBE NEWSWIRE) -- Asensus Surgical, Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and the patient, announced today that it plans to release fourth quarter and full year 2023 financial and operating results after the market closes on Thursday, March 21, 2024. The Company will host a conference call to discuss these results starting at 4:30 p.m. ET the same day. The call will be concurrently
